Clinical research in Brazil – New horizons, new challenges

Unraveling the Abbreviated Development Path

COVID-19: What facilities is ANVISA providing at this time of crisis?

Why are 24% of drug registrations still rejected?

API, BPF and drug dossier - How to align the processes to ensure success in registration?

NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?

Publication of the new API regulatory framework: what is essential to know?